These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30426287)

  • 21. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
    Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
    J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic properties of non-vaccinia poxviruses.
    Ricordel M; Foloppe J; Pichon C; Findeli A; Tosch C; Cordier P; Cochin S; Quémeneur E; Camus-Bouclainville C; Bertagnoli S; Erbs P
    Oncotarget; 2018 Nov; 9(89):35891-35906. PubMed ID: 30542506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
    André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
    Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma.
    Xu B; Ma R; Russell L; Yoo JY; Han J; Cui H; Yi P; Zhang J; Nakashima H; Dai H; Chiocca EA; Kaur B; Caligiuri MA; Yu J
    Nat Biotechnol; 2018 Nov; ():. PubMed ID: 30475349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
    Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
    Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
    Miller DM; Trowbridge RM; Desai A; Drews RE
    J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
    Havunen R; Santos JM; Sorsa S; Rantapero T; Lumen D; Siurala M; Airaksinen AJ; Cervera-Carrascon V; Tähtinen S; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2018 Dec; 11():109-121. PubMed ID: 30569015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
    Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
    J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
    Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
    J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precision immunoprofiling by image analysis and artificial intelligence.
    Koelzer VH; Sirinukunwattana K; Rittscher J; Mertz KD
    Virchows Arch; 2019 Apr; 474(4):511-522. PubMed ID: 30470933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combatting mucosal melanoma: recent advances and future perspectives.
    Tyrrell H; Payne M
    Melanoma Manag; 2018 Sep; 5(3):MMT11. PubMed ID: 30459941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.
    Miyamoto S; Nomura R; Sato K; Awano N; Kuse N; Inomata M; Izumo T; Terada Y; Furuhata Y; Bae Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Feb; 49(2):160-164. PubMed ID: 30452687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
    Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
    Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between Cell Receptors and Tumor Cell Sensitivity to Oncolytic Enteroviruses.
    Lipatova AV; Le TH; Sosnovtseva AO; Babaeva FE; Kochetkov DV; Chumakov PM
    Bull Exp Biol Med; 2018 Nov; 166(1):58-62. PubMed ID: 30450519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Identification of Immunological Biomarkers in Kidney Cancers.
    Lopez-Beltran A; Henriques V; Cimadamore A; Santoni M; Cheng L; Gevaert T; Blanca A; Massari F; Scarpelli M; Montironi R
    Front Oncol; 2018; 8():456. PubMed ID: 30450335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
    Jansen CS; Prokhnevska N; Kissick HT
    Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.